{
  "source": "PA-Notification-Danziten.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1467-1\nProgram Prior Authorization/Notification\nMedication Danziten™ (nilotinib)\nP&T Approval Date 1/2025\nEffective Date 4/1/2025\n1. Background:\nDanziten™ (nilotinib) is a kinase inhibitor indicated for the treatment of adult patients with newly\ndiagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic\nphase, as well as treatment of adult patients with chronic phase (CP) and accelerated phase Ph+\nCML resistant to or intolerant to prior therapy that included imatinib.1 The National Cancer\nComprehensive Network (NCCN) recommends the use of Danziten for primary or follow-up\nCML therapy in all stages. NCCN also recommends Danziten for the treatment of Philadelphia\nchromosome-positive B-cell acute lymphoblastic leukemia (B-ALL) as well as for the treatment\nof soft tissue sarcoma of pigmented villonodular synovitis/tenosynovial giant cell tumor. 2\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of 19\nyears, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or under\nsome circumstances. Some states also mandate usage of other Compendium references. Where such\nmandates apply, they supersede language in the benefit document or in the notification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Danziten will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Chronic Myeloid Leukemia\n1. Initial Authorization\na. Danziten will be approved based on the following criterion:\n(1) Diagnosis of chronic myeloid leukemia\nAuthorization will be issued for 12 months.\n2. Reauthorization\n© 2025 UnitedHealthcare Services, Inc.\n1\na. Danziten will be approved based on the following criterion:\n(1) Patient does not",
    "oid leukemia\nAuthorization will be issued for 12 months.\n2. Reauthorization\n© 2025 UnitedHealthcare Services, Inc.\n1\na. Danziten will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Danziten therapy\nAuthorization will be issued for 12 months.\nC. Acute Lymphoblastic Leukemia (Ph+B-ALL)\n1. Initial Authorization\na. Danziten will be approved based on the following criterion:\n(1) Diagnosis of Philadelphia chromosome-positive B-cell acute lymphoblastic\nleukemia (Ph+ B-ALL)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Danziten will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Danziten therapy\nAuthorization will be issued for 12 months.\nD. Soft Tissue Sarcoma\n1. Initial Authorization\na. Danziten will be approved based on the following criterion:\n(1) Diagnosis of pigmented villonodular synovitis/tenosynovial giant cell tumor\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Danziten will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Danziten therapy\nAuthorization will be issued for 12 months.\nE. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category\nof Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n2\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automa",
    "twithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Danziten [package insert]. Woburn, MA: Azurity Pharmaceuticals, Inc.; November\n2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed\nDecember 3, 2024.\nProgram Prior Authorization/Notification - Danziten (nilotinib)\nChange Control\n1/2025 New program.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}